Annual Meeting Home Past & Future Meetings

Back to Annual Meeting Program

Does Every Patient with Breast Cancer Need a Sentinel lymph Biopsy?
*Heather M King, *Susan Koelliker, *Christina Raker, *David Edmonson, *Don Dizon, Jennifer Gass
Women and Infants Hospital, Providence, RI

Objective: Could the use of Axillary Ultrasound Fine needle Aspiration (AXUSFNA) eliminate the need for SLNB in a group of breast cancer patients? We aim to identify the AXUSFNA false negative cohort and describe their characteristics in comparison to the AXUSFNA true positive cohort.
Design: Retrospective Chart Review (1/1/2006-8/1/2009)
Setting: Women and Infants Hospital (WIH) a primary teaching hospital
Patients: Breast Cancer patients who had AXUSFNA identified in radiology registry at WIH. Cross-referenced with tumor registry node positive patients. Study cohort: 134
Main Outcome Measures: AXUSFNA, SLNB and Axillary lymph node dissection (ALND) final pathology. Variables: age, BMI, surgery, histology, grade, lymphovascular invasion (LVI) on final pathology and core biopsy, Bloom Richardson’s score (BRS), tumor size, DCIS, DCIS grade, DCIS%, and receptor status. AXUSFNA data included number of nodes, node size and node description.
Results: Ax US FNA Sensitivity 64.9%, AxUSFNA False Negative Rate 35.1%. Smaller tumor, greater DCIS%, absent extracapsular extension, and small metastatic focus were predictive of false negative AxUSFNA. Multivariable logistic regression revealed extracapsular extension no longer significant.
Conclusions: Axillary US/FNA has a FNR of 35%, too high to omit a sentinel node biopsy in patients with a negative AxUSFNA. Remove Suspicious nodes on US and patients with LVI on core from FN cohort and FNR becomes 15%. This approaches 11% FNR seen in SLNB following neoadjuvant chemotherapy and the FNR of 10% in B-32. Correlation between LVI on final pathology and core biopsy is poor. Sensitivity was 24%. 65% had benign appearing nodes on ultrasound which 50% contained macro metastasis. Therefore, until genomic analysis supplants nodal assessment in determining adjuvant recommendation SLNB remains the most accurate tool for axillary staging.

Back to Annual Meeting Program


Abstract Submission Deadline:
May 5, 2014

Housing Deadline:
August 13, 2014

Early Bird Registration Deadline:
August 11, 2014
© 2018 New England Surgical Society. All Rights Reserved. Privacy Policy.